Anebulo Pharmaceuticals (ANEB) Receivables - Other (2020 - 2024)
Anebulo Pharmaceuticals (ANEB) posted quarterly Receivables - Other of -$214606.0 for Q4 2024, down 187.47% quarter-over-quarter from $245362.0 in Q3 2024.
Anebulo Pharmaceuticals (ANEB) Receivables - Other (2020 - 2024) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Receivables - Other for 2 consecutive years, with -$214606.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Receivables - Other changed N/A year-over-year to -$214606.0; the TTM figure through Jun 2020 stood at $3500.0 (changed N/A YoY), while the FY2020 annual figure was $3500.0, changed N/A from the prior year.
- Receivables - Other fell to -$214606.0 in Q4 2024 per ANEB's latest filing, from $245362.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $245362.0 in Q3 2024 and bottomed at -$214606.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -214,606.00 |
| Dec 31, 2024 | -214,606.00 |
| Sep 30, 2024 | 245,362.00 |
| Sep 30, 2024 | 245,362.00 |
| Jun 30, 2020 | 3,500.00 |
| Jun 30, 2020 | 3,500.00 |